8-K Announcements
6Material company update
Apr 29, 2026·SEC
Material company update
Apr 3, 2026·SEC
Material company update
Mar 4, 2026·SEC
AbbVie Inc.(ABBV)Earnings, Financials & Key Ratios
ABBV•NYSE
91.4× P/E·Price updated Jun 19, 2026
AboutAbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.Show more
- Revenue$61.16B+8.6%
- EBITDA$28.23B+61.1%
- Net Income$4.23B-1.2%
- EPS (Diluted)2.37-0.8%
- Gross Margin70.24%+0.3%
- EBITDA Margin46.16%+48.4%
- Operating Margin32.85%+102.5%
- Net Margin6.91%-9.0%
- ROE6214.71%+9895.4%
ABBV Key Insights
AbbVie Inc. (ABBV) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Dividend Aristocrat: 43 years of consecutive increases
- ✓Excellent 3Y average ROE of 2104.0%
- ✓FCF machine: 29.1% free cash flow margin
- ✓High quality earnings: Operating CF exceeds net income
- ✓Healthy dividend yield of 3.0%
- ✓Healthy 5Y average net margin of 12.9%
✗Weaknesses
- ✗Dividend payout exceeds 100% of earnings
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when ABBV posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ABBV Price & Volume
AbbVie Inc. (ABBV) stock price & volume — 10-year historical chart
Loading chart...
ABBV Growth Metrics
AbbVie Inc. (ABBV) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years10.34%
5 Years5.95%
3 Years1.75%
TTM8.57%
Profit CAGR
10 Years-1.95%
5 Years-1.75%
3 Years-29.06%
TTM-1.22%
EPS CAGR
10 Years-2.74%
5 Years-2.72%
3 Years-29.03%
TTM-1.36%
Return on Capital
10 Years15.87%
5 Years15.02%
3 Years14.44%
Last Year21.48%
ABBV Recent Earnings
AbbVie Inc. (ABBV) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 11/12 qtrs (92%)●Beat Revenue 12/12 qtrs (100%)
Q2 2026Latest
Apr 29, 2026Metric
Actual
Est
EPS
$2.65+2.3%
$2.59
Rev
$15.0B+1.9%
$14.7B
Q1 2026
Feb 4, 2026Metric
Actual
Est
EPS
$2.71+2.3%
$2.65
Rev
$16.6B+1.2%
$16.4B
Q4 2025
Oct 31, 2025Metric
Actual
Est
EPS
$1.86+5.1%
$1.77
Rev
$15.8B+1.2%
$15.6B
Q3 2025
Jul 31, 2025Metric
Actual
Est
EPS
$2.97+3.1%
$2.88
Rev
$15.4B+2.6%
$15.0B
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 29, 2026 | $2.65vs $2.59+2.3% | $15.0Bvs $14.7B+1.9% |
| Q1 2026 | Feb 4, 2026 | $2.71vs $2.65+2.3% | $16.6Bvs $16.4B+1.2% |
| Q4 2025 | Oct 31, 2025 | $1.86vs $1.77+5.1% | $15.8Bvs $15.6B+1.2% |
| Q3 2025 | Jul 31, 2025 | $2.97vs $2.88+3.1% | $15.4Bvs $15.0B+2.6% |
Based on last 12 quarters of dataView full earnings history →
ABBV Peer Comparison
AbbVie Inc. (ABBV) competitors in Specialty and biologics-focused pharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 JNJ | 550.4B | 228.39 | 39.45 | 4.3% | 27.26% | 31.69% | 0.51 | |
 MRK | 281.25B | 113.87 | 15.64 | 1.18% | 28.12% | 36.14% | 0.96 | |
 PFE | 143.46B | 25.22 | 18.54 | -1.65% | 11.83% | 8.34% | 0.78 | |
 BMY | 110.25B | 54.00 | 15.65 | -0.22% | 15.01% | 38.96% | 2.55 | |
 LLY | 1.04T | 1098.13 | 47.85 | 44.7% | 34.98% | 101.17% | 1.60 | |
 AMGN | 182.2B | 337.60 | 23.72 | 9.92% | 20.95% | 89.41% | 6.31 | |
 GILD | 153.66B | 123.76 | 18.25 | 2.39% | 30.99% | 42.33% | 1.09 | |
 BIIB | 29.02B | 196.58 | 22.26 | 1.39% | 13.92% | 7.55% | 0.38 |
Compare ABBV vs Peers
AbbVie Inc. (ABBV) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ABBV Income Statement
AbbVie Inc. (ABBV) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 28.22B | 32.75B | 33.27B | 45.8B | 56.2B | 58.05B | 54.32B | 56.33B | 61.16B |
Revenue Growth % | 10.06% | 16.08% | 1.57% | 37.69% | 22.69% | 3.3% | -6.44% | 3.71% | 8.57% |
Cost of Goods Sold | 7.04B | 7.72B | 7.44B | 15.39B | 17.45B | 17.41B | 20.41B | 16.9B | 18.2B |
COGS % of Revenue | 24.95% | 23.56% | 22.36% | 33.59% | 31.04% | 30% | 37.58% | 30.01% | 29.76% |
Gross Profit | 21.18B▲ 0% | 25.04B▲ 18.2% | 25.83B▲ 3.2% | 30.42B▲ 17.8% | 38.75B▲ 27.4% | 40.64B▲ 4.9% | 33.9B▼ 16.6% | 39.43B▲ 16.3% | 42.96B▲ 8.9% |
Gross Margin % | 75.05% | 76.44% | 77.64% | 66.41% | 68.96% | 70% | 62.42% | 69.99% | 70.24% |
Gross Profit Growth % | 6.92% | 18.22% | 3.16% | 17.77% | 27.4% | 4.87% | -16.58% | 16.3% | 8.94% |
Operating Expenses | 11.63B | 18.65B | 12.84B | 19.05B | 20.83B | 22.52B | 21.15B | 30.29B | 22.86B |
OpEx % of Revenue | 41.21% | 56.95% | 38.61% | 41.6% | 37.06% | 38.8% | 38.93% | 53.77% | 37.39% |
Selling, General & Admin | 6.29B | 7.4B | 6.94B | 11.3B | 12.35B | 15.26B | 12.87B | 14.75B | 14.01B |
SG&A % of Revenue | 22.31% | 22.59% | 20.87% | 24.67% | 21.97% | 26.29% | 23.7% | 26.19% | 22.91% |
Research & Development | 5.33B | 10.75B | 6.79B | 7.75B | 8.05B | 6.51B | 7.67B | 12.79B | 9.1B |
R&D % of Revenue | 18.9% | 32.83% | 20.42% | 16.93% | 14.32% | 11.21% | 14.13% | 22.71% | 14.87% |
Other Operating Expenses | 0 | 500M | -890M | 0 | 432M | 753M | 599M | 2.75B | -241M |
Operating Income | 9.54B▲ 0% | 6.38B▼ 33.1% | 12.98B▲ 103.4% | 11.36B▼ 12.5% | 17.92B▲ 57.7% | 18.12B▲ 1.1% | 12.76B▼ 29.6% | 9.14B▼ 28.4% | 20.09B▲ 119.9% |
Operating Margin % | 33.83% | 19.49% | 39.03% | 24.81% | 31.89% | 31.21% | 23.49% | 16.22% | 32.85% |
Operating Income Growth % | 2.19% | -33.13% | 103.4% | -12.48% | 57.74% | 1.08% | -29.59% | -28.38% | 119.89% |
EBITDA | 11.05B | 8.15B | 15B | 17.83B | 26.45B | 26.58B | 21.45B | 17.52B | 28.23B |
EBITDA Margin % | 39.15% | 24.88% | 45.09% | 38.94% | 47.06% | 45.79% | 39.5% | 31.11% | 46.16% |
EBITDA Growth % | 4.91% | -26.24% | 84.09% | 18.89% | 48.28% | 0.53% | -19.29% | -18.33% | 61.1% |
D&A (Non-Cash Add-back) | 1.5B | 1.76B | 2.02B | 6.47B | 8.52B | 8.47B | 8.7B | 8.39B | 8.14B |
EBIT | 8.88B | 6.54B | 10.21B | 5.85B | 15.41B | 15.71B | 8.47B | 6.52B | 9.49B |
Net Interest Income | -1B | -1.14B | -1.51B | -2.28B | -2.38B | -2.04B | -1.68B | -2.16B | -2.63B |
Interest Income | 146M | 204M | 275M | 174M | 39M | 186M | 540M | 648M | 266M |
Interest Expense | 1.15B | 1.35B | 1.78B | 2.45B | 2.42B | 2.23B | 2.22B | 2.81B | 2.89B |
Other Income/Expense | -1.82B | -1.19B | -4.56B | -7.96B | -4.93B | -4.64B | -6.51B | -5.42B | -13.49B |
Pretax Income | 7.73B▲ 0% | 5.2B▼ 32.7% | 8.43B▲ 62.1% | 3.4B▼ 59.7% | 12.99B▲ 282.3% | 13.48B▲ 3.8% | 6.25B▼ 53.6% | 3.72B▼ 40.5% | 6.6B▲ 77.5% |
Pretax Margin % | 27.39% | 15.87% | 25.33% | 7.42% | 23.11% | 23.21% | 11.51% | 6.6% | 10.79% |
Income Tax | 2.42B | -490M | 544M | -1.22B | 1.44B | 1.63B | 1.38B | -570M | 2.36B |
Effective Tax Rate % | 31.29% | -9.43% | 6.46% | -36.02% | 11.09% | 12.11% | 22.03% | -15.34% | 35.83% |
Net Income | 5.31B▲ 0% | 5.69B▲ 7.1% | 7.88B▲ 38.6% | 4.62B▼ 41.4% | 11.54B▲ 150.0% | 11.84B▲ 2.5% | 4.86B▼ 58.9% | 4.28B▼ 12.0% | 4.23B▼ 1.2% |
Net Margin % | 18.82% | 17.36% | 23.69% | 10.08% | 20.54% | 20.39% | 8.95% | 7.59% | 6.91% |
Net Income Growth % | -10.82% | 7.12% | 38.6% | -41.44% | 150.04% | 2.55% | -58.91% | -12.03% | -1.22% |
Net Income (Continuing) | 5.31B | 5.69B | 7.88B | 4.62B | 11.55B | 11.85B | 4.87B | 4.29B | 4.23B |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 21M | 28M | 33M | 37M | 39M | 42M |
EPS (Diluted) | 3.30▲ 0% | 3.68▲ 11.5% | 5.28▲ 43.5% | 2.72▼ 48.5% | 6.45▲ 137.1% | 6.63▲ 2.8% | 2.72▼ 59.0% | 2.39▼ 12.1% | 2.37▼ 0.8% |
EPS Growth % | -9.09% | 11.52% | 43.48% | -48.48% | 137.13% | 2.79% | -58.97% | -12.13% | -0.84% |
EPS (Basic) | 3.31 | 3.69 | 5.30 | 2.73 | 6.48 | 6.65 | 2.73 | 2.40 | 2.37 |
Diluted Shares Outstanding | 1.6B | 1.55B | 1.48B | 1.67B | 1.78B | 1.78B | 1.77B | 1.77B | 1.77B |
Basic Shares Outstanding | 1.6B | 1.54B | 1.48B | 1.67B | 1.77B | 1.77B | 1.77B | 1.77B | 1.78B |
Dividend Payout Ratio | 77.36% | 98.12% | 80.77% | 167.16% | 80.24% | 84.85% | 216.72% | 257.71% | 275.84% |
ABBV Balance Sheet
AbbVie Inc. (ABBV) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 21.22B | 16.95B | 49.52B | 24.17B | 27.93B | 28.46B | 33B | 25.58B | 29.06B |
Cash & Short-Term Investments | 9.79B | 8.06B | 39.92B | 8.48B | 9.83B | 9.23B | 12.82B | 5.55B | 5.26B |
Cash Only | 9.3B | 7.29B | 39.92B | 8.45B | 9.75B | 9.2B | 12.81B | 5.52B | 5.23B |
Short-Term Investments | 486M | 772M | 0 | 30M | 84M | 28M | 2M | 31M | 28M |
Accounts Receivable | 5.09B | 5.38B | 5.43B | 8.82B | 9.98B | 11.25B | 11.15B | 10.92B | 12.59B |
Days Sales Outstanding | 65.82 | 60 | 59.56 | 70.3 | 64.8 | 70.76 | 74.96 | 70.75 | 75.13 |
Inventory | 1.6B | 1.6B | 1.81B | 3.31B | 3.13B | 3.58B | 4.1B | 4.18B | 4.95B |
Days Inventory Outstanding | 83.21 | 75.9 | 88.96 | 78.52 | 65.44 | 75.02 | 73.29 | 90.28 | 99.27 |
Other Current Assets | 0 | 0 | 0 | 0 | 0 | 4.4B | 4.93B | 4.93B | 6.26B |
Total Non-Current Assets | 49.56B | 42.41B | 39.6B | 126.39B | 118.6B | 110.34B | 101.71B | 109.58B | 104.9B |
Property, Plant & Equipment | 2.8B | 2.88B | 2.96B | 5.25B | 5.11B | 4.93B | 4.99B | 5.13B | 6.37B |
Fixed Asset Turnover | 10.07x | 11.36x | 11.23x | 8.73x | 11.00x | 11.76x | 10.89x | 10.97x | 9.61x |
Goodwill | 15.79B | 15.66B | 15.6B | 33.12B | 32.38B | 32.16B | 32.29B | 34.96B | 35.64B |
Intangible Assets | 27.56B | 21.23B | 18.65B | 82.88B | 75.95B | 67.44B | 55.61B | 60.07B | 52.64B |
Long-Term Investments | 2.09B | 1.42B | 93M | 293M | 277M | 241M | 304M | 279M | 299M |
Other Non-Current Assets | 1.33B | 1.21B | 2.29B | 4.85B | 4.88B | 5.57B | 8.51B | 9.14B | 9.95B |
Total Assets | 70.79B▲ 0% | 59.35B▼ 16.2% | 89.11B▲ 50.1% | 150.56B▲ 69.0% | 146.53B▼ 2.7% | 138.81B▼ 5.3% | 134.71B▼ 2.9% | 135.16B▲ 0.3% | 133.96B▼ 0.9% |
Asset Turnover | 0.40x | 0.55x | 0.37x | 0.30x | 0.38x | 0.42x | 0.40x | 0.42x | 0.46x |
Asset Growth % | 7.09% | -16.15% | 50.15% | 68.96% | -2.68% | -5.27% | -2.95% | 0.33% | -0.89% |
Total Current Liabilities | 16.64B | 17.24B | 15.59B | 28.66B | 35.19B | 29.54B | 37.84B | 38.75B | 43.29B |
Accounts Payable | 1.47B | 1.55B | 1.45B | 2.28B | 2.88B | 2.93B | 3.69B | 2.94B | 3.59B |
Days Payables Outstanding | 76.42 | 73.11 | 71.24 | 53.99 | 60.3 | 61.5 | 65.94 | 63.59 | 72.02 |
Short-Term Debt | 6.42B | 5.31B | 3.75B | 8.68B | 12.67B | 4.3B | 7.19B | 6.8B | 8.75B |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1.14B | 1.61B | 0 | 16.04B | 17.85B | 20.93B | 25.16B | 27.01B | 25.63B |
Current Ratio | 1.28x | 0.98x | 3.18x | 0.84x | 0.79x | 0.96x | 0.87x | 0.66x | 0.67x |
Quick Ratio | 1.18x | 0.89x | 3.06x | 0.73x | 0.70x | 0.84x | 0.76x | 0.55x | 0.56x |
Cash Conversion Cycle | 72.61 | 62.79 | 77.27 | 94.83 | 69.95 | 84.28 | 82.31 | 97.43 | 102.38 |
Total Non-Current Liabilities | 49.05B | 50.56B | 81.7B | 108.81B | 95.9B | 91.98B | 86.47B | 93.05B | 93.9B |
Long-Term Debt | 30.95B | 35B | 62.98B | 77.53B | 64.16B | 59.12B | 52.17B | 60.34B | 59.61B |
Capital Lease Obligations | 0 | 0 | 271M | 853M | 738M | 771M | 762M | 720M | 711M |
Deferred Tax Liabilities | 5.17B | 3.79B | 3.9B | 9.33B | 8.98B | 8.69B | 8.63B | 7.63B | 7.96B |
Other Non-Current Liabilities | 12.92B | 11.76B | 14.57B | 21.09B | 22.02B | 23.4B | 24.91B | 24.38B | 25.62B |
Total Liabilities | 65.69B | 67.8B | 97.29B | 137.47B | 131.09B | 121.52B | 124.31B | 131.8B | 137.19B |
Total Debt | 37.37B | 40.31B | 67.09B | 87.06B | 77.58B | 64.19B | 60.12B | 67.84B | 69.07B |
Net Debt | 28.07B | 33.02B | 27.16B | 78.61B | 67.83B | 54.99B | 47.31B | 62.32B | 63.84B |
Debt / Equity | 7.33x | - | - | 6.65x | 5.03x | 3.71x | 5.78x | 20.17x | - |
Debt / EBITDA | 3.38x | 4.95x | 4.47x | 4.88x | 2.93x | 2.41x | 2.80x | 3.87x | 2.45x |
Net Debt / EBITDA | 2.54x | 4.05x | 1.81x | 4.41x | 2.56x | 2.07x | 2.20x | 3.56x | 2.26x |
Interest Coverage | 7.72x | 4.86x | 5.72x | 2.38x | 6.36x | 7.04x | 3.81x | 2.32x | 3.28x |
Total Equity | 5.1B▲ 0% | -8.45B▼ 265.7% | -8.17B▲ 3.2% | 13.1B▲ 260.3% | 15.44B▲ 17.9% | 17.29B▲ 12.0% | 10.4B▼ 39.9% | 3.36B▼ 67.6% | -3.23B▼ 196.0% |
Equity Growth % | 9.94% | -265.71% | 3.24% | 260.27% | 17.86% | 11.99% | -39.86% | -67.64% | -195.96% |
Book Value per Share | 3.18 | -5.46 | -5.51 | 7.83 | 8.69 | 9.72 | 5.86 | 1.90 | -1.82 |
Total Shareholders' Equity | 5.1B | -8.45B | -8.17B | 13.08B | 15.41B | 17.25B | 10.36B | 3.33B | -3.27B |
Common Stock | 18M | 18M | 18M | 18M | 18M | 18M | 18M | 18M | 18M |
Retained Earnings | 5.46B | 3.37B | 4.72B | 1.05B | 3.13B | 4.78B | -1B | -7.9B | -15.49B |
Treasury Stock | -11.92B | -24.11B | -24.5B | -2.26B | -3.14B | -4.59B | -6.53B | -8.2B | -9.15B |
Accumulated OCI | -2.73B | -2.48B | -3.6B | -3.12B | -2.9B | -2.2B | -2.31B | -1.93B | -1.14B |
Minority Interest | 0 | 0 | 0 | 21M | 28M | 33M | 37M | 39M | 42M |
ABBV Cash Flow Statement
AbbVie Inc. (ABBV) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 9.96B | 13.43B | 13.32B | 17.59B | 22.78B | 24.94B | 22.84B | 18.81B | 19.03B |
Operating CF Margin % | 35.3% | 40.99% | 40.05% | 38.4% | 40.53% | 42.97% | 42.05% | 33.38% | 31.12% |
Operating CF Growth % | 41.46% | 34.81% | -0.77% | 32% | 29.5% | 9.51% | -8.44% | -17.66% | 1.19% |
Net Income | 5.31B | 5.69B | 7.88B | 4.62B | 11.55B | 11.85B | 4.82B | 4.29B | 4.23B |
Depreciation & Amortization | 1.5B | 1.76B | 2.02B | 6.47B | 8.52B | 8.47B | 8.7B | 8.39B | 8.14B |
Stock-Based Compensation | 365M | 421M | 430M | 753M | 692M | 671M | 747M | 911M | 955M |
Deferred Taxes | 1.24B | 424M | 700M | -2.33B | -898M | -1.93B | -2.89B | -1.45B | -492M |
Other Non-Cash Items | 1.53B | 6.26B | 3.62B | 7.96B | 4.24B | 6.15B | 8.65B | 9.45B | 8.6B |
Working Capital Changes | 9M | -1.13B | -1.33B | 106M | -1.32B | -258M | 2.81B | -2.78B | -2.36B |
Change in Receivables | -391M | -591M | -74M | -929M | -1.32B | -1.46B | 66M | 207M | -1.49B |
Change in Inventory | 93M | -226M | -231M | -40M | -142M | -686M | -417M | -319M | -234M |
Change in Payables | 425M | 190M | -1.12B | 1.51B | 1.63B | 1.6B | 3.84B | 177M | 951M |
Cash from Investing | -274M | -1.01B | 596M | -37.56B | -2.34B | -623M | -2.01B | -20.82B | -6.64B |
Capital Expenditures | -529M | -638M | -552M | -798M | -787M | -695M | -777M | -974M | -1.21B |
CapEx % of Revenue | 1.87% | 1.95% | 1.66% | 1.74% | 1.4% | 1.2% | 1.43% | 1.73% | 1.98% |
Acquisitions | -308M | -736M | -1.14B | -39.61B | -1.9B | -794M | -1.22B | -17.49B | -204M |
Investments | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 167M | 1.39B | 366M | 774M | 13M | -2.83B | -5.27B |
Cash from Financing | -5.51B | -14.4B | 18.71B | -11.5B | -19.04B | -24.8B | -17.22B | -5.21B | -12.72B |
Debt Issued (Net) | -2M | 3.23B | 26.25B | -2.68B | -8.41B | -12.43B | -4.15B | 7.35B | -327M |
Equity Issued (Net) | -1.41B | -12.01B | -629M | -978M | -934M | -1.49B | -1.97B | -1.71B | -808M |
Dividends Paid | -4.11B | -5.58B | -6.37B | -7.72B | -9.26B | -10.04B | -10.54B | -11.03B | -11.66B |
Share Repurchases | -1.41B | -12.01B | -629M | -978M | -934M | -1.49B | -1.97B | -1.71B | -980M |
Other Financing | 30M | -31M | -544M | -124M | -430M | -840M | -562M | 172M | 68M |
Net Change in Cash | 4.2B▲ 0% | -2.01B▼ 147.9% | 32.63B▲ 1720.4% | -31.48B▼ 196.4% | 1.3B▲ 104.1% | -545M▼ 142.0% | 3.61B▲ 762.9% | -7.29B▼ 301.8% | -295M▲ 96.0% |
Free Cash Flow | 9.43B▲ 0% | 12.79B▲ 35.6% | 12.77B▼ 0.1% | 16.79B▲ 31.5% | 21.99B▲ 31.0% | 24.25B▲ 10.3% | 22.06B▼ 9.0% | 17.83B▼ 19.2% | 17.82B▼ 0.1% |
FCF Margin % | 33.42% | 39.05% | 38.39% | 36.66% | 39.13% | 41.77% | 40.62% | 31.65% | 29.13% |
FCF Growth % | 43.72% | 35.61% | -0.13% | 31.46% | 30.97% | 10.27% | -9.02% | -19.17% | -0.09% |
FCF per Share | 5.88 | 8.27 | 8.61 | 10.04 | 12.37 | 13.64 | 12.44 | 10.06 | 10.04 |
FCF Conversion (FCF/Net Income) | 1.88x | 2.36x | 1.69x | 3.81x | 1.97x | 2.11x | 4.70x | 4.40x | 4.50x |
Interest Paid | 1.1B | 1.22B | 1.79B | 2.62B | 2.71B | 2.55B | 2.47B | 2.81B | 0 |
Taxes Paid | 1.7B | -35M | 1.45B | 1.67B | 3.65B | 2.99B | 4.7B | 4.06B | 0 |
ABBV Key Ratios
AbbVie Inc. (ABBV) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | 138.75% | 109.09% | - | - | 187.45% | 80.9% | 72.34% | 35.13% | 62.18% | 6214.71% |
Return on Invested Capital (ROIC) | 22.03% | 20.59% | 16.58% | 44.7% | 15.4% | 15.37% | 17.47% | 14.72% | 11.11% | 23.86% |
Gross Margin | 77.25% | 75.05% | 76.44% | 77.64% | 66.41% | 68.96% | 70% | 62.42% | 69.99% | 70.24% |
Net Margin | 23.22% | 18.82% | 17.36% | 23.69% | 10.08% | 20.54% | 20.39% | 8.95% | 7.59% | 6.91% |
Debt / Equity | 7.95x | 7.33x | - | - | 6.65x | 5.03x | 3.71x | 5.78x | 20.17x | - |
Interest Coverage | 8.53x | 7.72x | 4.86x | 5.72x | 2.38x | 6.36x | 7.04x | 3.81x | 2.32x | 3.28x |
FCF Conversion | 1.18x | 1.88x | 2.36x | 1.69x | 3.81x | 1.97x | 2.11x | 4.70x | 4.40x | 4.50x |
Revenue Growth | 12.16% | 10.06% | 16.08% | 1.57% | 37.69% | 22.69% | 3.3% | -6.44% | 3.71% | 8.57% |
Related:ABBV Dividend History·ABBV Revenue History·ABBV Price History·ABBV P/E History·ABBV Financial Ratios·ABBV Institutional Holders
ABBV SEC Filings & Documents
AbbVie Inc. (ABBV) SEC filings — annual & quarterly reports (10-K, 10-Q)
ABBV Frequently Asked Questions
AbbVie Inc. (ABBV) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
AbbVie Inc. (ABBV) reported $61.16B in revenue for fiscal year 2025. This represents a 291% increase from $15.64B in 2010.
AbbVie Inc. (ABBV) grew revenue by 8.6% over the past year. This is steady growth.
Yes, AbbVie Inc. (ABBV) is profitable, generating $4.23B in net income for fiscal year 2025 (6.9% net margin).
Dividend & Returns
Yes, AbbVie Inc. (ABBV) pays a dividend with a yield of 3.03%. This makes it attractive for income-focused investors.
AbbVie Inc. (ABBV) has a return on equity (ROE) of 6214.7%. This is excellent, indicating efficient use of shareholder capital.
AbbVie Inc. (ABBV) generated $18.70B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.